Semler Scientific Price Target Increased to $71.00

Shares of Semler Scientific (NASDAQ:SMLR) received a positive update from Lake Street Capital, which has raised its price target from $40.00 to $71.00. This recommendation, announced on Friday, comes along with a "buy" rating for the stock.

Lake Street Capital's new price target indicates a potential upside of 27.41% from the stock's most recent closing price.

Semler Scientific Stock Overview

On Friday, during mid-day trading, Semler Scientific saw a drop of $5.43, reaching a price of $55.73 per share. The trading volume for the day was notable, totaling 1,106,436 shares, which is significantly higher than the average volume of 433,983 shares. The company has been trading with a 50-day simple moving average of $59.91 and a 200-day simple moving average of $39.99. Over the last year, Semler Scientific's stock has had a low point of $20.88 and a high of $81.56, with a market capitalization of $516.57 million. Its price-to-earnings ratio stands at 27.29, and the stock has a beta of 1.18.

Earnings Report Insights

Semler Scientific recently announced its earnings results on November 4th. The company reported earnings of $0.72 per share for the quarter, surpassing analysts' expectations, which were set at $0.37, by a significant margin of $0.35. The firm's net profit margin is reported to be 27.00%, and it has achieved a return on equity of 20.31%, with total revenues standing at $13.51 million.

Institutional Investments in Semler Scientific

Recent activities from institutional investors highlight growing interest in Semler Scientific. For instance, Newbridge Financial Services Group Inc. acquired a new stake worth approximately $34,000 in the second quarter. Meanwhile, Quest Partners LLC increased its investment in the company by 48.0% in the third quarter, now owning 2,520 shares valued at $59,000 after purchasing an additional 817 shares. Similarly, US Bancorp DE expanded its holdings by 60.8%, owning 3,064 shares worth $72,000, thanks to an additional 1,158 shares acquired during the same period. Other investors, such as Sanctuary Advisors LLC, also initiated new positions valued around $104,000, while Rhumbline Advisers raised its stake by 27.1%, owning 6,197 shares now valued at $213,000. Overall, hedge funds and institutional investors control approximately 49.37% of the company's stock.

Company Profile of Semler Scientific

Semler Scientific, Inc. specializes in providing technology solutions aimed at improving the operational efficiency and clinical effectiveness of healthcare providers across the United States. Among its product offerings is QuantaFlo, a blood flow test that can be performed in-office within four minutes, allowing healthcare providers to integrate blood flow measurements into their assessments of patients' vascular conditions.

stocks, investment, earnings